2024/01/25 by Thomas Boehmeke · 1 voice
Medicine · Neuroscience · #Fibromyalgia and Chronic Fatigue Syndrome Research #Long-Term Effects of COVID-19 #Olfactory and Sensory Function Studies
paper · pdf · doi:10.7759/cureus.52935
openalex publication_date 2024/01/25 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/22
After a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, approximately 10-20% of patients are affected by the post-COVID syndrome (PCS). This condition leads to a variety of functional complaints, including symptoms of fatigue. To date, there is still no adequate treatment option. Five patients are presented, including the self-observation of one of the authors, in whom the administration of amifampridine as an "off-label use" led to a normalization of the unphysiologically increased need for sleep with a simultaneous increase in the Bell score. This effect was confirmed in a double-blind discontinuation trial (the medication was discontinued on a trial basis) in two of the patients. The five patients, who were previously unable to lead a normal life due to their fatigue symptoms, were able to return to everyday life after treatment with amifampridine. This offers hope to millions of affected patients.